Genmab — April 2026
-
Hemab Therapeutics files for a $100 million IPO https://www.renaissancecapital.com/IPO-Center/News/118229/Coagulation-disorder-biotech-Hemab-Therapeutics-files-for-a-$100-million-IP
-
What the filing does reveal, though, is that Hemab plans to use the IPO raise for sutacimig, an investigational bispecific antibody being trialed for Glanzmann thrombasthenia and Factor VII deficiency—both congenital and severe bleeding disorders that have no subcutaneous prophylactic treatment options. https://www.biospace.com/business/ipo-tracker-2026
-
Hemab Therapeutics Receives FDA Breakthrough Therapy Designation for Sutacimig in Glanzmann Thrombasthenia https://www.hemab.com/news-items/hemab-therapeutics-receives-fda-breakthrough-therapy-designation-for-sutacimig-in-glanzmann-thrombasthenia
-
@Raun: Det er den klassiske "Buy on rumour, sell on fact". Hvis man har en god mavefornemmelse for pipeline ("rumour"), så er det nu man skal købe og så (evt.) sælge, når resultaterne foreligger og kursen brager op.
-
@concillado..... Den tese synes jeg ikke passer ind i dette scenarie.
-
posters/presentations at SGO Annual Meeting on April 10-13, 2026 via https://www.genmabmedicalaffairs.com/congress?filv1=28
-
Tisotumab vedotin plus carboplatin or pembrolizumab in recurrent or metastatic cervical cancer: 5-year results from the innovaTV 205/ENGOT-cx8/GOG-3024 study https://www.sciencedirect.com/science/article/pii/S0090825826008012
-
Godmorgen
-
AACR
1761 / 6 - Tissue Factor expression is associated with B7-H4-mediated immune evasion in ovarian clear cell carcinoma and with response to tisotumab vedotin in preclinical models https://www.abstractsonline.com/pp8/#!/21436/presentation/4318 -
Trial Update from innovaTV 205/ENGOT-cx8/GOG-3024: Tisotumab Vedotin Combinations in Recurrent or Metastatic Cervical Cancer https://oncodaily.com/industry/innovatv-205-engot-cx8
-
” Very happy to see ADCs finally moving earlier in cervical cancer — because in real life, using them late is often too late!!!
Recurrent/metastatic cervical cancer is still an unmet need. In daily practice, when we give Tisotumab Vedotin (TV) after immunotherapy, patients are often already compromised — fistulas, nephrostomies, frailty. That’s not when you unlock the full potential of an ADC. -
The 5-year innovaTV 205 data clearly show that TV-based combinations (triplet/quadruplet regimens) are active and durable, especially in 1L, with response rates up to ~66% and OS approaching 2+ years.
If we believe in these drugs, we should use them earlier — not as a last resort. This shift toward early lines is not just interesting. It’s necessary.”
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind